Abstract. The bioavailabilities and activities of three amcinonide preparations and Betnovate cream were assessed using three multiple-dosage regimen .vasoconstrictor assays in 10 volunteers. Applications were made once daily, twice daily and every alternate day with an initial three times daily loading dose applied on the first day only. Blanching responses first increased and then decreased due to tachyphylaxis. It is proposed that clinicall1lhe most advantageous dosage regimen is a once daily application with no loading dose.
Patients may become resistant to topical steroids after constant use [7] . Such tachyphylaxis has also been demonstrated in the vasoconstrictor assay for corticosteroids, with considerable recovery occurring if ã rest period' intervenes in the dosage regimen [2, 4, 5] . The authors' previous studies using a non-occluded multiple-dosage regimen involveda three times daily application [2] : less frequent administration might produce less marked tachyphylaxis. Lack of clinical studies comparing the use of potent topical steroids in twice daily, daily and alternate-day regimens [3] prompted investigation of such regimens in the repeated-application skin-blanching test.
Materials and Methods

Corticosteroid Formulations
Topical preparations (Cyanamid of Great Britain Ltd.) containing amcinonide (16a., 17a.-cyclopentylidenedioxy-9a.-fluoro-II~, 21-dihydroxy-1 ,4-pregnadiene-3,20-dione 21-acetate) were amcinonide cream, 0.1%, amcinonide cream, 0.025%, and amcinonide ointment, 0.1 %. The 0.1 % formulations are marketed in Europe as Penticort. Betnovate cream (betamethasone velerate 0.1 %) was employed as a standard preparation for comparative purposes.
Volunteers 10 volunteers were selected ITom an experienced panel as those demonstrating consistency of response to a standard preparation (Betnovate cream) in the vasoconstrictor test [I] . None had received topical corticosteroid application for at least 3 months prior to the study.
Methods
Dosage Regimens. Each regimen included three applications on day 1, the loadingdose (at 0,4 and 7 h), the preparations thereafterbeing applied (days 2-5) in each of three modes: (a) twice daily at 9.30 hand 16.30 h; (b) once daily, at 9.30 h, and (c) on alternatd ays, at 9.30 h on days 3 and 5. Days 6 and 7 were rest periods. From day 8, the procedure was repeated at the same sites, omitting two of the applications of the loading dose.
Application Procedure and Result Assessment. 5 :!: 1mg of each formulationwere rubbed (1 min) into a 7 x 7 mm area on each forearmof 10volunteers, using a glassrod, and with referenceto a randomization chart. Holes in a plastic sheet located the application sites: indelibleink markersfacilitatedsubsequentapplication. Blanching was estimated using a ()...4scale with half- Double-blind estimations of skin blanching were made at each application time immediately before reapplying the formulationsand at additional times indicated on the figure.Siteswereunguardedand volunteers livednorm~so as to mimic domiciliaryuse of topical steroids.
Results and Discussion
The results were summed for all volunteers at each time, expressedas a percentage of the total possible score [1] and were plotted as functions of time. Results for all four steroid preparations were similar therefore only those for amcinonide cream 0.1% are shown~s an example ( fig. 1) .
The blanching responses are in table I. The results for the individual scores in each preparation/regimen were submitted to a computer-assisted analysis of variance followed by applicatioQ of the Studentized range test on the preferred 'square root transformation' data [1, 10] . Statistically signifi- ., " regimens. An arrow represents steroid application and a line indicates an additional readingtime. 2 Obtained by planimetry ofthe blanching profiles. 3 The sum ofthe scoresfor all volunteers over all reading times. 4 The sum of the % total possible scores for all volunteers over all readingtimes. 5 The Tmil 0 mean value is the square root transformation of the sum of scores (Tm) divided by the number of volunteers (10) .The minimum significant range value k =1.53 (p = 0.05), i.e. if two Tm/lO vaprls differby more than 1.53 there is a significant difference between the two preparations/regimens [6] .
cant differencesexisted between the values (F = 1.91, p < 0.05), the minimum significant range value k being 1.53 (p=0.05, 12 means, 99 d. f.).
The three times daily application on day 1 produced a large blanching response and subsequent application caused tachyphylaxis, irrespective of potency or dosage regimen. Sites recovered over days 6 and 7 and the blanching profiles obtained during the second week showed a lower degree of tolerance than for days 1-5 ( fig. 1) . The incidence of tachyphylaxis in the second week was less than that demonstrated by Barry and Woodford [2] using the more drastic regimen of three times daily application. The areas under the blanching curves for both weekswere similar, mean values forthe first week being 49.1% (range 45.7-54.4%, depending on formulation/regimen) and for the second week, 50.9% (range 45.6-54.3%) of the total values (table I) .
The rank order of blanching effectiveness for the application regimens was (a) amcinonide cream 0.025% and Betnovate cream: twice daily> daily> alternate day; (b)amcinonide cream 0.1% and ointment 0.1% daily> twice daily> alternate da: Statistical analysis suggested that the 0.1c ream was significantly more potent (p =0.05) (a) in the once daily regimen than when applied on alternate days,and (b)than amcinonide cream 0.025% and Betnovate cream applied in the once daily mode. 138 Woodford/Haigh/Barry Amcinonide ointment was significantly more potent than Betnovate cream in the once daily regimen.
Clinical Significance: Preftrred Dosage Regimen
Results suggestthat once daily application should be preferred clinically to twice daily use.for the followingreasons.
(1) It was the only regimen permitting statistical differentiation at the 5% level between formulations,e.g. .the apparent superiority of the 0.1% cream over the 0.025% preparation and Betnovate cream. This confirms potency classificationspreviously obtained in the single6 hour occluded vasoconstrictor assay of (a) the 0.1% amcinonide preparations'being 'very potent' by the United Kingdom Mims classification [8] , and (b)the 0.025% and Betnovatecreams as 'potent' [10, 11] .
(2) Less total steroid would be applied, thus miniJPising unwanted side-effects of topical cifrticosteroid therapy.
(3) Once daily application should facilitate patient compliance and the use of smaller quantities is more economic.
(4) If therapy commenced with amcinonide cream 0.1% in a once daily regimen (this preparation/regimen produces the largest blanching parameters), once the condition was stabilised it could be maintained by changing to the 0.025% formulation. Because three times daily application ijn day 1 produced considerable tachyphys not evident on day 8 it may be advant,ageousin the clinical situation to omit the It>ading dose.
The observation [9] that once daily application of 0.1% halcinonide cream was almost as effective as three times daily application in atopic dermatitis suggests that less frequent use of very potent formulations in certain skin disorders may be preferable.
Bioavailability of 0.1% Preparations
Amcinonide ointment 0.1% was rather less effective than the corresponding cream in all dosage regimens (table I) . This agrees with the formulation of these two preparations: both contain the steroid completely in solution, but whereas it is nearing saturation in the cream, the ointment system is less saturated [Cyanamid of Great Britain, personal commun.].
